Johnson & Johnson starts trial of COVID-19 vaccine after producing immune response in primates – MarketWatch

Johnson & Johnson
JNJ,
-1.69%
said Thursday that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The vaccine provided a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates, the company said. Based on the strength of the data, a Phase 1/2a first-i…

Click here to view the original article.